Ardelyx Investors Face November Deadline in Securities Fraud Lawsuit

The complaint filed by Schall, Brown & Schwartz LLP alleges that Ardelyx failed to disclose mounting reimbursement barriers that hampered patient access to its medications. According to the filing, the company faced increasingly stringent prior authorization and step-edit requirements that delayed new-patient starts and prescription fulfillment. These operational challenges reportedly undermined commercial performance, rendering the company’s public statements during the class period materially misleading.

Shareholders who incurred financial losses due to these disclosures are encouraged to contact attorneys Brian Schall or David Schwartz to review their legal options. While the class has not yet received formal certification, those who suffered damages may participate in the recovery process without necessarily serving as lead plaintiff. The firm operates out of Los Angeles and focuses on shareholder rights and securities litigation.